Let Activefol.io Invest in LLY on Your Behalf.

Stock Detail Header
  • Active Investing
  • Personalized Strategy
  • Low Monthly Fees
Get Started
Stock Details
  • PRICE$115.70
  • % CHANGE0.4%


Course of Action


Sentiment (10 days)

  •  Strong Buy
  •  Buy
  •  Hold
  •  Sell
  •  Strong Sell


  • BullishBullish
  • BearishBearish
  • SentimentSentiment
  • BarPrice

What is Activefol.io?

Activefol.io, our automated portfolio management platform, is designed to manage individual portfolios using the latest technology. Its proprietary system is designed to screens, monitors and invest in elite stocks like "ELI LILLY AND COMPANY (LLY)" using is unique Artificial Intelligence signals. It is designed to augment investors profit potential.

Activefol.io produces short-term trades which makes it an ideal tool for investing in tax-deferred accounts such as IRAs and Roth IRAs. If also works great in individual and joint taxable accounts. Just be aware that Activefol.io produces short-term investments that can be taxed at different rates than long-term investments. Make sure you understand your tax situation before using Activefol.io.

Using Activefol.io is easy. It connects to your account located at one of our supported Broker / Dealers. Our current Partners are offering brokerage services in the United States only. You will need a minimum of $25,000 deposited in your account, enable your margin to allow continuous investing to take place. Once enabled, Activefol.io will start working on your behalf.


There are clear benefits associated with using an automated portfolio management system such as Activefol.io to help you reach your financial goals. Activefol.io simplifies stock investing down to a few easy steps. It invests for you, using your personalized strategy, while you attend more important life events.

Using Activefol.io feels like having a professional Portfolio Manager working for you to help you reach your financial goals.

Activefol.io actively invests in the most positive components of the S&P 500® on your behalf. Its Artificial Intelligence signal takes into account emotional and rational indicators to provide key intelligence, 24/7. It 'trades on the news' taking advantage of price changes and trends by listening to market changes.

Activefol.iois one of the first automated management platforms to take advantage of Government grade listening technology. It consumes market data and other specialized data feeds natively to produce a dynamic picture of the market.

Try Activefol.io today!

You can test Activefol.io in simulation mode, risk free, Stock Circles today.

Get started now - and see where active automated trading can take you.

Disclaimer: Past performance may not be indicative of future results. ACTIVEFOL.IOg, like other investment methods, rely on favorable market conditions to provide positive returns.


Sue Mahony to Retire as President of Lilly Oncology

Eli Lilly and Company (NYSE: LLY) announced today that Sue Mahony, Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of August after 18 years of service with the company. Mahony is also a member of Lilly's executive committee.

"On behalf of our executive team and the company, I want to thank Sue for her leadership over the past 18 years," said David A. Ricks, Lilly's chairman and chief executive officer. "Her passion for patients and strong sense of purpose are inspiring to all of us."

Mahony led Lilly Oncology through the integration of ImClone, successfully launched several key brands—including Verzenio™—and most recently led the refocusing of the company's oncology R&D strategy. Prior to this, as senior vice president of human resources and diversity, Mahony played a key role in restructuring the company into business units.

Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in Europe for Schering-Plough, Amgen and Bristol-Myers Squibb. At Lilly, Mahony has held senior leadership positions in product development, Six Sigma, marketing and general management roles.

"What I've appreciated over the years is the opportunity to participate in something greater than myself," said Mahony. "We make medicines that help patients with cancer live longer. What a privilege it's been to wake up each morning with that as my life's work."

Lilly is considering internal and external candidates to succeed Mahony.

Get Started today! - Risk Free

Investors who like ELI LILLY AND COMPANY (LLY) also like

Most Talked About Stocks on Stock Circles

Stock Bubbles